Polyplus-transfection® SA, today announces the appointment of Marc Funk, newly appointed CEO of Recipharm and former CEO of Lonza, to its Board of Directors.
Strasbourg, France, March 30, 2021 – Polyplus-transfection® SA, the leading biotechnology company that supports the gene and cell therapy market by supplying innovative transfection solutions, today announces the appointment of Marc Funk, newly appointed CEO of Recipharm and former CEO of Lonza, to its Board of Directors.
Marc Funk is a strong addition to the Board with deep expertise and knowledge from his twenty years operating in the pharma and biotech industry. Recently appointed as CEO of major CDMO Recipharm, Marc is an entrepreneur and global business leader with a track record of seven consecutive years of growth to build the world’s largest contract manufacturing company in the pharma biotech industry at Lonza. With his strong global network of industry contacts spanning Europe, the US and the Far East, Marc is well positioned to support the Board and management team in driving value and success for the company. Marc Funk is a key member of the MedTalent® network of ArchiMed, the healthcare dedicated private equity firm.
“It has been my pleasure to know and follow Marc’s work for many years,” said Mario Philips, CEO, Polyplus-transfection. “There are only a handful of people globally with his expertise and knowledge of the life science industry. I am confident that with him on board, Polyplus-transfection will be able drive innovation with deeper insights of the evolving production technology priorities in the gene and cell therapy sector.”
“It is a privilege to join the Board of Polyplus-transfection, which is a leading company in a sector very close to my heart,” said Marc Funk. “I am excited about the future of the rapidly expanding gene and cell therapy market and to represent a company at the cutting edge of its field.”